Abstracts tagged "randomized trials and rheumatoid arthritis (RA)"

Abstract Number: 1005 • 2013 ACR/ARHP Annual Meeting
Generalization and Extrapolation Of Treatment Effects From Clinical Studies In Rheumatoid Arthritis
Sandhya C. Nair¹, Wietske Kievit², R W Janse³, Johannes WJ Bijlsma⁴, Floris Lafeber⁵, Jaap Fransen⁶ and P.M.J. Welsing⁷, ¹Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Department of Rheumatology and DREAM registry, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Medical student, Utrecht, Netherlands, ⁴Dept of Rheumatology and Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁷Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: Randomized clinical trials (RCTs) are accepted as the ‘gold standard’ to evaluate the efficacy/effectiveness of treatment. However, generalizing results from RCTs to daily practice…
Abstract Number: 358 • 2012 ACR/ARHP Annual Meeting
Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis
Debby den Uyl¹, Marieke M. ter Wee¹, Maarten Boers², Alexandre Voskuyl³, P.J.S.M. Kerstens⁴, Mike T. Nurmohamed⁵, Hennie G. Raterman¹, Dirkjan van Schaardenburg⁵, N. van Dillen⁴, B.a.C Dijkmans¹ and W.F. Lems¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Reade | Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Early, intensive treatment of rheumatoid arthritis (RA) with combination therapy (COBRA therapy) considerably lowers disease activity and suppresses radiological progression. Although proven to be…
Abstract Number: 1303 • 2012 ACR/ARHP Annual Meeting
Achieving Comprehensive Disease Control in Long-Standing or Early Rheumatoid Arthritis Patients Treated with Adalimumab Plus Methotrexate Versus Methotrexate Alone
Edward Keystone¹, Ferdinand C. Breedveld², Désirée van der Heijde³, Ronald F. van Vollenhoven⁴, Stefan Florentinus⁵, Freddy Faccin⁶, Shufang Liu⁷, Hartmut Kupper⁸ and Arthur Kavanaugh⁹, ¹University of Toronto, Professor of Medicine, Toronto, ON, Canada, ²Dept of Rheumatology C1R, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Karolinska Institute, Stockholm, Sweden, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott, Abbott Park, IL, ⁸Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁹UCSD School of Medicine, La Jolla, CA
Background/Purpose: Effective treatment of rheumatoid arthritis (RA) patients (pts) aims to suppress inflammation, preserve physical function, and prevent structural damage, which together represent the hallmarks…
Abstract Number: 775 • 2012 ACR/ARHP Annual Meeting
Long-Term Outcomes of Early Rheumatoid Arthritis Patients Initiated with Adalimumab Plus Methotrexate Compared with Methotrexate Alone Following a Targeted Treatment Approach
Roy Fleischmann¹, Ronald F. van Vollenhoven², Josef S. Smolen³, Paul Emery⁴, Stefan Florentinus⁵, Suchitrita S. Rathmann⁶, Hartmut Kupper⁷ and Arthur Kavanaugh⁸, ¹Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ²Karolinska Institute, Stockholm, Sweden, ³Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁴Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁵AbbVie, Rungis, France, ⁶Abbott, Abbott Park, IL, ⁷Immunology Development, Abbott GmbH and Co. KG, Ludwigshafen, Germany, ⁸UCSD School of Medicine, La Jolla, CA
Background/Purpose: In rheumatoid arthritis (RA), anti-TNF therapy is considered following 3-6 months of failed methotrexate (MTX) treatment. Some patients (pts), particularly those with many risk…
Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
Susanna Proudman¹, Llew Spargo¹, Cindy Hall¹, Leah McWilliams¹, Anita Lee¹, Maureen Rischmueller², Robert Gibson³, Michael James¹ and Leslie G. Cleland¹, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…
Abstract Number: 469 • 2012 ACR/ARHP Annual Meeting
Intra Articular Injections in Patients with Rheumatoid Arthritis: Analyses From the Behandelstrategiën Study
E. Gvozdenovic¹, L. Dirven¹, M. van den Broek², Kh Han³, T.H.E. Molenaar⁴, R. Landewe⁵, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ⁴Dept of Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁶Rheumatology, VU University medical center, Amsterdam, Netherlands
Background/Purpose: Intra articular (IA) corticosteroid injections aim at amelioration of symptoms of local inflammation in rheumatoid arthritis (RA). Some patients also report a systemic effect.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].